In partnership with biotech start-up Aneuryst, Long Island University is developing fasudil, a Rho-kinase inhibitor with the potential to redefine care for subarachnoid hemorrhage (SAH), one of the deadliest forms of stroke. The project’s application to the National Institutes of Health (NIH) Small Business Innovation Research program earned a perfect score, an almost unprecedented achievement in federal funding.
